A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Sequencing data is all well and good, but what does it mean?
Can the company's $1.5bn valuation be justified when last year it took just $23.5m in orders?
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.